The area under the curve for serum cortisol concentrations over 24 h (AUC 24 ) was essentially unaltered at all doses. Study 2. Plasma levels over days 7 to 28 were 100.3 ؎ 5.9 pg/mL (mean ؎ SEM) for MF DPI 400 g bid, and 181.0 ؎ 10.9 pg/mL for 800 g bid. Although there were relatively low levels of suppression (19 to 25%) at earlier time points for MF DPI 400 g bid, serum cortisol AUC 24 levels at day 28 were similar to placebo. MF DPI 800 g bid and oral prednisone both decreased serum cortisol AUC 24 levels at days 7 to 28 by 28.0 ؎ 8.3% and 67.2 ؎ 3.6%, respectively. The response to cosyntropin was normal in 15, 14, 11, and 1 of the patients in the placebo, MF DPI 400 g bid, MF DPI 800 g bid, and prednisone groups, respectively. Study 3. MF MDI caused even less systemic exposure than by DPI. MF MDI 800 g bid (24.0 ؎ 3.1%) and FP (51.7 ؎ 3.8%) caused a significant decrease in serum cortisol AUC 24 on days 14 to 28. MF MDI 400 g bid was similar to placebo treatment at all time points. Conclusions: The MF 800-g bid dosage (1,600 g/d), which is twice the highest projected clinical dosage, represents the lower limit for consistently detectable systemic effects of MF.
I
nhaled glucocorticoids are front-line drugs in the treatment of persistent asthma. [1] [2] [3] [4] [5] [6] [7] Although the mechanisms underlying their beneficial effects in asthma are not fully known, a key initiating event is binding of the glucocorticoid to cytosolic receptors. 1, 4 Since glucocorticoid receptors are present in a multitude of cell types and mediate a wide range of cellular responses on binding to their natural ligand (endogenous cortisol), the potential for adverse effects exists if systemic levels of glucocorticoid are sufficiently elevated. Indeed, long-term administration of oral glucocorticoids is associated with potential adverse effects, such as adrenal suppression, altered bone metabolism, and impairment of growth in children. 4 The use of inhaled steroids in the long-term treatment of asthma has been generally found to be safe at recommended therapeutic dos-es. 4 However, concerns have been raised, and there is a strong desire to develop inhaled glucocorticoids with therapeutic activity at the lung greatly exceeding the potential for systemic effects. 8 Mometasone furoate (MF) is a highly potent topical steroid currently available in dermatologic, nasal, and oral inhaled preparations. MF has been formulated as a powder-lactose mixture (one part MF to 5.8 parts lactose) administered by a novel breath-actuated dry powder inhaler (DPI) developed to provide uniform delivery of respirable particles. MF DPI is highly effective in patients with mild-tomoderate persistent asthma. 9, 10 MF also has been formulated for administration by oral inhalation with a metered-dose inhaler (MDI). In initial clinical studies using the MDI device, the formulation contained a microcrystalline suspension of MF in chlorofluorocarbon (CFC) propellant. However, to eliminate the use of CFCs, MF has recently been formulated for MDI with a non-CFC propellant (hydrofluoroalkane-227) that is considered to be a suitable alternative to CFCs by the European Union Committee for Proprietary Medicinal Products. In vitro studies have shown MF to be among the most potent glucocorticoids in inhibiting cytokine production, histamine release, and eosinophil survival. 11, 12 MF was among the most potent glucocorticoids analyzed in vitro for binding to the glucocorticoid receptor and stimulation of gene expression associated with the anti-inflammatory response. 13 The present report examines the potential of MF administered by either DPI or MDI to exert systemic effects with doses that include and exceed those recommended for the treatment of persistent asthma. 9 The potential for systemic effects has been investigated by using tests for the suppression of the hypothalamic-pituitary-adrenal (HPA) axis. These tests include sensitive time-integrated serum cortisol concentration measurements, as well as cosyntropin stimulation and urinary cortisol excretion. 4, 14 Additionally, plasma MF concentrations were monitored.
Materials and Methods
All three studies were conducted at the same research center (Arkansas Research Medical Testing Center) in patients with a history of mild-to-moderate persistent asthma. The study protocols and statements of informed consent were approved by the Arkansas Research Human Volunteers Research Committee prior to the start of the study. Subjects gave written informed consent prior to enrolling into the study.
Study 1
Sixty patients were studied in a randomized, evaluator-blind, placebo-controlled, parallel-group investigation of the multipledose effects of MF on HPA axis function. The patients had FEV 1 scores from 60 to 80% of predicted and demonstrated reversibility of bronchospasm in response to albuterol. The patients were nonsmokers, had no recent history of upper respiratory tract infection, and, at the time of screening, had morning serum cortisol concentrations of 16.6 Ϯ 0.5 g/dL (range, 11 to 24 g/dL). Patients were excluded who were pregnant, nursing, or had received oral corticosteroids within 6 months, IM corticosteroids within 1 year, or inhaled corticosteroids at doses greater than the maximum label dose. All patients were determined to be in good health on the basis of medical history, and results of physical examination, ECG, and routine laboratory tests.
Patients were randomly assigned to one of five treatment groups (12 patients in each group): MF, 400 g qd (morning); MF, 200 g bid (morning and evening), for a total of 400 g/d; MF, 800 g qd (morning); MF, 1,200 g qd (morning); and placebo DPI qd. All treatments were administered by inhalation with a breath-activated DPI device for 28 consecutive days. For patients receiving MF, the DPI delivered 100 g per inhalation. Patients receiving placebo treatment took 12 inhalations from the DPI.
Seven days prior to initial treatment administration, patients were taken off treatment with their current asthma medications, stabilized on a regimen of oral theophylline, and allowed to use an albuterol MDI as needed. At least 72 h prior to initial treatment, patients were confined to the study center. During the study period, blood samples were taken for the determination of serum cortisol and MF concentrations. Blood samples (3 mL) for cortisol content were taken on day 2 (8 am and 11 pm); days 6, 13, 20, and 27 (11 pm); days 1, 7, 14, 21, and 28 at hourly intervals from 4 am to 10 am, and then at noon, 4 pm, 8 pm, and 11 pm. The lowest of the day-2 and day-1 8 am serum cortisol concentrations were used as the baseline values for subsequent safety evaluations. Blood samples (7 mL) for MF analysis were collected on days 7, 14, 21, and 28 at 8 am, 8:30 am, 9 am, 9:30 am, 10 am, 11 am, 12 noon, 2 pm, 4 pm, and 8 pm. The 8 am and 8 pm samples were collected prior to treatment administration. Blood was collected in heparinized tubes and centrifuged for 15 min (3,500 revolutions/min; 4°C) to remove the RBCs. One milliliter of plasma sample was removed for cortisol determination and the remainder was used for MF determination. Samples were frozen and stored (Ϫ 20°C) in plastic tubes until assayed.
Urine was collected for the determination of free cortisol concentrations in 24-h blocks from 11 pm on day 2 to 11 pm on day 1 (prior to treatment) and similarly on treatment days 6 and 7, 13 and 14, 20 and 21, and 27 and 28. Volunteers were urged to void prior to the beginning of these urine collection periods. Collected urine was refrigerated. One gram of boric acid was added to each block in a plastic container at the start of collection. A 50-mL aliquot was obtained from each well-mixed 24-h block sample. Samples were frozen and stored (Ϫ 20°C) until analyzed.
Serum cortisol determinations were performed by a commercial radioimmunoassay at Smith-Kline Beecham Laboratories (St. Louis, MO). Urinary free cortisol determinations were performed by high-performance liquid chromatography at SmithKline Beecham Laboratories. MF concentrations were determined using high-performance liquid chromatography with tandem mass spectrometric detection method by Phoenix International Life Sciences (Ville Saint-Laurent, Canada). The lower limit of quantitation (LOQ) of this assay was 50 pg/mL.
The derived variables obtained from days 0, 7, 14, 21, and 18 measurements of serum cortisol were as follows: observed maximum concentration (Cmax); time to observed maximum; area under the serum concentration-time curve from 11 pm to 11 pm of the next day (AUC 24 ); area under the serum concentrationtime curve from 11 pm to 8 pm; area under the serum concentration-time to the last measurable serum concentration (AUCtf); area under the serum concentration-time curve from 0 to 12 h; and cortisol concentration at 8 am (C8am); and time to final measured concentration (in hours).
Areas under the curve were calculated using the trapezoidal rule. MF levels below the limit of quantitation (50 pg/mL) were considered zero.
Cosyntropin stimulation tests were performed on day 29, the day after the last study treatment was administered. Blood samples were drawn and subsequently analyzed for serum cortisol content prior to and 30 min after a 0.25-mg IM injection of cosyntropin. The criteria for a normal response to cosyntropin were as follows: (1) the baseline serum cortisol concentration should be Ͼ 5 g/dL; (2) the concentration obtained at 30 min after the cosyntropin injection should show an increment of at least 7 g/dL above the basal concentration; (3) the 30-min postcosyntropin-injection serum cortisol concentration should be Ͼ 18 g/dL.
Analyses of variance were performed for the 24-h urinary free cortisol excretion and the derived cortisol serum variables for each day, extracting effects due to treatment (dose). The placebo group was not used in the analysis of MF concentrations, since all but one concentration (50.4 pg/mL) were below the limits of quantitation. Pairwise comparisons were made using the least significant difference, without adjustment for multiple comparisons. The contrast between the highest dose (1,200 g) and placebo group on day 28 was considered the most important contrast for the cortisol data. Data have been summarized by means and SDs.
Study 2
In addition to the above study, which primarily examined single daily doses of MF, a second study to evaluate the potential for systemic exposure of MF following DPI administration was focused on twice-daily dosing. This was also a randomized, evaluator-blind, multiple-dose, parallel-dose groups study with both placebo and positive controls in 64 patients with mild-tomoderate asthma. Patients had pretreatment morning serum cortisol concentrations of 15.2 Ϯ 0.5 g/dL (range, 10 to 26 g/dL). Patients were assigned to one of the four treatment groups (16 patients in each group) for 29 consecutive days: MF DPI, 400 g bid, as two inhalations of 200 g/inhalation in the morning and the evening; MF DPI, 800 g bid, as two inhalations of 400 g/inhalation in the morning and the evening; prednisone, 10 mg qd, as two 5-mg tablets in the morning; and two inhalations of placebo lactose powder (same as the vehicle for the active MF treatments) in the morning and the evening.
Patient inclusion and exclusion criteria were the same as described in study 1. Seven days prior to initial treatment administration, patients were taken off treatment with their current asthma medications, stabilized on a regimen of oral theophylline, and allowed to use only an albuterol MDI, as needed. Patients were confined to the study center starting 3 days prior to initial treatment. Blood sampling for serum cortisol determination was performed as for study 1. Blood samples for plasma MF determination were obtained in the morning on day 1, as well as prior to the morning treatment administration, and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 h after the morning treatment on study days 7, 14, 21, and 28. The 12-h sample was collected prior to the administration of the evening treatment. At least 14 days prior to the administration of the initial dose and approximately 2 h after the morning treatment on day 29, a 30-min cosyntropin test was performed as described in study 1.
Plasma concentrations of MF were determined as described in study 1. Individual concentrations were used for pharmacokinetic analysis using model-independent methods. The Cmax and time to observed maximum were the observed values. The AUCtf and the area under the serum concentration-time curve from 0 to 12 h were calculated by the linear trapezoidal rule.
Systemic exposure to inhaled MF was assessed by monitoring serum cortisol concentrations, based on the serum cortisol AUC 24 prior to initiation of treatment (baseline) and on study days 7, 14, 21, and 28, as described in study 1.
Study 3
This study was similar to study 2, except that MF was administered by MDI containing a non-CFC propellant and that the active comparator was fluticasone propionate (FP) MDI instead of prednisone. Sixty-four adult patients with a history of moderate persistent asthma were enrolled in this multiple-dose, randomized, evaluator-blind, parallel-treatment-groups evaluation of potential for systemic exposure. Patient inclusion and exclusion criteria; pretreatment regimen; blood sampling times for MF, assay, and analysis of MF concentrations; blood sampling, assay, and evaluation of serum cortisol concentrations; and cosyntropin testing were the same as described for study 2. At screening, patients had morning serum cortisol concentrations of 12.8 Ϯ 0.3 g/dL (range, 10 to 18 g/dL). Patients were treated in the morning and the evening for 29 consecutive days. The four treatment groups (n ϭ 16, each group) were as follows: MF MDI, 400 g bid, as two inhalations of 200 g; MF MDI, 800 g bid, as four inhalations of 200 g; FP MDI, 880 g bid, as four inhalations of 220 g; and placebo, four puffs from an MDI containing a non-CFC propellant. The non-CFC propellant used for MF and placebo treatment was hydrofluoroalkane-227.
Cortisol data were analyzed by one-way analysis of variance, with pairwise comparisons made using the least significant difference (each ␣ ϭ 0.05, two sided without adjusting for multiple comparisons) considering the most important contrast exists between the highest dose of MF and placebo. The primary end point for cosyntropin testing was the number (percent) of patients with a normal response, which was compared by a Fisher's Exact Test.
Results

Study 1
There were a total of 60 patients (12 in each treatment group) whose ages were 35.1 Ϯ 1.2 years (mean Ϯ SEM; range, 18 to 49 years) and whose weights were 171.1 Ϯ 3.0 lb (range, 127 to 220 lb). There were 32 female and 28 male patients. The only patient receiving inhaled corticosteroids (beclomethasone dipropionate, two puffs as needed) prior to the study was in the placebo group.
In the treatment groups with the lower MF doses (200 g/bid and 400 g/qd), plasma MF concentrations were below the LOQ at all sampling times in many patients and less than twice the LOQ in many patients up to 800 g/qd. Many patients had only one or two concentrations above the LOQ. As a result, Cmax was considered the primary exposure variable for all treatment groups (Table 1) . There was essentially no exposure in patients treated with MF, 200 g bid, and only minimal exposure in patients treated with MF, 400 g qd, as reflected in the low mean Cmax values in relation to the LOQ. There was a dose-related increase in MF plasma concentration that was statistically significant (p Ͻ
The primary pharmacodynamic parameter used to assess systemic exposure to MF following DPI was based on the AUC 24 of the serum cortisol concentration time curve (Fig 1) . Since the final 11 pm blood sample was not obtained for 30 of the 60 patients on day 21, the area under the serum concentration-time curve from 0 to 18 h was analyzed for this day. The only statistically significant (p Ͻ 0.05) mean decrease from placebo was 18%, which was observed for the 400 g qd treatment group on day 28. Overall, the mean serum cortisol area under the curve for the MF DPI groups, as percentages of placebo, ranged from 82 to 107%. There were neither dose-related nor time-related changes observed. Additionally, there were no significant ) . Individually, all patients had morning serum cortisol concentrations within the normal range on the days examined.
Compared to placebo, there were no significant (p Ͼ 0.05) treatment group differences in urinary free cortisol (data not shown). Values ranged from 17 to 30 g/24 h at baseline and from 10 to 34 g/24 h during the treatment.
After 28 consecutive days of treatment, all patients had a normal serum cortisol response to a 30-min IM injection of cosyntropin (data not shown). All patients had serum cortisol values at baseline of at least 10 g/dL, except for one patient in the placebo group with a value of 9 g/dL. Serum cortisol concentrations in all patients at 30 min after cosyntropin were increased by at least 7 g/dL to values Ͼ 18 g/dL.
Study 2
There were 64 patients whose ages were 36.2 Ϯ 0.9 years (mean Ϯ SEM; range, 18 to 47 years) and whose weights were 179.2 Ϯ 3.1 lb (range 129 to 240 lb). There were 46 male patients and 18 female patients. The only patient receiving inhaled corticosteroids (beclomethasone dipropionate, two puffs as needed) prior to the study was in the prednisone group.
Following MF DPI, 400-g bid, or MF DPI, 800-g bid (ie, 800 to 1,600 g/d), plasma concentrations of MF were low and often nonquantifiable (Fig 2) . Thus, mean concentrations were associated with high variability. At both dose levels, MF concentrations were not quantifiable in some patients on some days. Due to the large variability in plasma MF concentrations, the derived pharmacokinetic parameters also showed large variability (Table 2 ) and the Cmax and AUCtf values at the 400-g and 800-g doses were not statistically significantly different (Table 2) .
For serum cortisol values, there was a treatmentrelated decrease in mean AUC 24 across the study period, with the placebo group having the highest values, followed by the MF, 400 g bid, group; the MF, 800 g bid, group; and the prednisone, 10 mg qd, group (Fig 3) . Despite imbalances in baseline AUC 24 among the treatment groups, analysis of covariance including baseline as a covariant indicated that it is reasonable to base inferences in this study on the analysis of actual mean cortisol values rather than the mean change from baseline cortisol values. The prednisone values were significantly (p Ͻ 0.01) lower than any other treatment group. While the values for the MF, 800 g bid, group were *Data are presented as mean (percent coefficient of variation). The limit for quantification for the assay is 50 pg/mL. The No. of patients in each group is 12, except for the 200-g bid dose on day 7 (n ϭ 11). lower than those for the MF, 400 g bid, group on corresponding days, the differences between them were not significant. For the MF, 400 g bid, group, AUC 24 h was marginally reduced from placebo by 10 to 25%, the 10% reduction on day 28 not being statistically significant. For the MF, 800 g bid, group, there were significant reductions from the corresponding placebo cortisol AUC 24 values of 40%, 26%, 25%, and 21% on study days 7, 14, 21, and 28, respectively. In contrast to the MF DPI groups, the oral prednisone group had significant and marked reductions of cortisol AUC 24 compared to placebo, from 64 to 72% (Fig 3) . After 29 consecutive days of treatment and at approximately 2 h after the final study treatment administration, the prednisone group had significantly (p Ͻ 0.01) lower mean serum cortisol levels both before (4.9 g/dL) and after (14.5 g/dL) stimulation with cosyntropin. The postcosyntropin stimulation mean serum cortisol concentration for the MF, 800 g bid, group (21 g/dL) was significantly (p Ͻ 0.05) less than for the placebo group (25 g/dL). The postcosyntropin stimulation mean serum cortisol concentration for the 400-g bid group (23 g/dL) was not significantly less than placebo. The proportion of patients whose postcosyntropin serum cortisol concentration was Ͼ 18 g/dL was 15 of 16 patients in the placebo group; 14 of 16 patients in the MF, 400 g bid, group; 11 of 16 patients in the MF, 800 g bid, group; and 1 of 16 patients in the prednisone, 10 mg qd, group. Mean plasma MF concentrations following multipledose pulmonary administration by DPI. MF was administered as 400 g bid or 800 g bid, and the plasma concentrations were determined over a 12-h period on days 7, 14, 21, and 28. The limit of quantitation is 50 pg/mL. The number of patients in each group was 16, except for the MF, 400 g bid, dose at time 0, and at 3 to 12 h when the number of patients was 15. 
Study 3
There were 64 patients included in the study whose ages were 36.0 Ϯ 0.9 years (mean Ϯ SEM; range 19 to 50 years) and whose weights were 176.4 Ϯ 3.8 lb (range, 125 to 250 lb). There were 38 male and 26 female patients. No patients were receiving inhaled corticosteroids prior to the study. Twice-daily administration of MF, 400 g, via MDI did not cause quantifiable plasma levels for 9 of 16 patients on one or more sampling days. In those patients in whom MF concentrations were quantifiable, concentrations were observed at sporadic time points and were generally close to the LOQ of the assay (Fig 4) , and mean concentrations were associated with high variability (about 100 to 200%). At 800 g bid, MF concentrations were quantifiable in most, but not all, patients with the mean MF concentrations higher and somewhat less variable than those observed at the 400-g dose. Due to the large variability in plasma MF concentrations, the derived pharmacokinetic parameters (Table 3) also showed large variability. For mean Cmax and AUCtf, values were generally twofold to threefold greater for the 800-g dose and these differences were significant for the AUCtf values. At either dose, there was no evidence for drug accumulation on repeated dosing.
Baseline serum cortisol AUC 24 values were not significantly different across treatment groups (Fig 5,  top, A) . Mean cortisol AUC 24 values for the MF, 400 g bid, group were not significantly different from the placebo group values on any treatment day (Fig  5, top, A) . For the MF, 800 g bid, group, AUC 24 values were significantly reduced from placebo values by 20%, 30%, and 22% on study days 14, 21, and 28, respectively. In comparison, the FP, 880 g bid, group had markedly reduced serum cortisol AUC 24 values compared to placebo of 43%, 44%, 55%, and 56% on study days 7, 14, 21, and 28, respectively (Fig  5, top, A) . Additionally, the mean AUC 24 values for the FP, 880 g bid, group were significantly suppressed, compared to those of the MF, 800 g bid, group. When individual serum cortisol AUC 24 values were examined, the lowest value in the placebo group was 130.5 g h/dL and this occurred on day 28 (Fig 5, bottom, B) . For the MF, 400 g bid, group, one patient had a lower value (128.5 g h/dL) than the lowest placebo value on day 14 (Fig 5, bottom,  B) . For the MF, 800 g bid, group, one patient had a lower value (124.5 g h/dL) than the lowest placebo value on day 14; six patients (range, 96 to 128.5 g h/dL) had a lower value on day 21; and two patients (118.5 g h/d and 121.5 g h/dL, respectively) had lower values on day 28. For the FP, 880 g bid, group, 9 patients had lower values (range, 1 to 124.5 g h/dL) than the lowest placebo value on day 7; 7 patients (range, 0 to 113.0 g h/dL) had lower values on day 14; 12 patients (range, 0 to 115.5 g h/dL) had lower values on day 21; and 13 patients (range, 0 to 130.0 g h/dL) had lower values on day 28 (Fig 5, bottom, B) . In spite of a marked reduction in serum cortisol AUC 24 for the FP, 880 g bid, group, all study patients had a normal response to cosyntropin stimulation following the last treatment dose on the last treatment day (day 29).
Discussion
Twice-daily dosing with MF by DPI at a high total dose of 1,600 g/d (study 2) was the lower limit for establishing consistent evidence of low levels of systemic exposure within the time frame studied, as demonstrated by moderately reduced mean serum cortisol AUC 24 values and failure to achieve a normal cosyntropin response in some patients. Additionally at this high dose, MF was detected in the plasma, although not in all patients. The effects of this dose of inhaled MF on HPA-axis function, as judged by mean serum cortisol AUC 24 values and postcosyntropin mean serum cortisol levels, were far less than those of prednisone, 10 mg qd po, over the same time period.
Although there were no statistically significant differences in plasma MF concentrations between the MF, 400 g bid, dose, and the MF, 800 g bid, dose administered by DPI, the 400-g bid dose showed a trend to be lower at all tested periods. Also, the MF, 400 g bid, dose had less of an effect on HPA-axis function. The lack of statistical difference between the doses in plasma MF concentrations is probably due to the high variability of MF concentrations, which were generally near or below the LOQ. While some suppression of the mean serum cortisol AUC 24 was observed in the first 3 weeks of the study, MF DPI, 400 g bid, did not significantly reduce the mean serum cortisol AUC 24 , compared to placebo, or the postcosyntropin mean serum cortisol level at the end of the treatment period.
Twice-daily dosing of MF by MDI (study 3) generated qualitatively similar results to that of analogous study using DPI administration. Slight systemic effects on the HPA-axis function were detected at MF, 800 g bid, but not MF, 400 g bid. However, the potential for systemic exposure appears to be even less with MDI administration. Comparing the MF plasma concentrations following DPI (Table 2 ) and MDI (Table 3 ) administration, there is considerably less systemic exposure following MDI than DPI. For example, on day 28 of MF, 800 g bid, the mean AUCtf was 1,029 pg h/mL using DPI but only 526 pg h/mL using MDI. Additionally, while a few patients (5 of 16) had abnormal cosyntropin test results following MF DPI, 800 g bid, none did following treatment with the same dose by MDI. However, the greater potential for systemic exposure following twice-daily administration of high doses of MF with DPI, compared to MDI, was not reflected by HPA-axis function as assessed by serum cortisol AUC 24 values at the later time points (day 21 and day 28).
Results with single daily dosages of MF DPI up to 1,200 g qd showed almost no effect on the HPA axis. Effects of MF on cortisol levels monitored as C8am, Cmax, or the AUC 24 of the serum cortisol concentrations, urinary free cortisol, and response to cosyntropin showed no significant differences from placebo, except for MF, 400 g qd, at day 28 on AUC 24 . In the context of no effect at other times or with higher doses of MF (even up to 1,200 g qd), this single data point that shows a small effect (18% decrease compared to placebo) does not appear to be clinically relevant. Additionally, the concentrations of plasma MF following the 400-g qd dose were negligible. Taken together, the present results place a lower bound of 800 g bid (1,600 g/d) on long-term dosing producing consistent systemic effects. This is twice the projected maximum dose. Single daily doses below this (up to 1,200 g) seem to have negligible systemic effects.
Due to the large diurnal variation in cortisol levels, single time point measures of serum cortisol concentrations (such as the C8am) are believed to be insensitive measures of HPA axis. 4, 14 However, the integrative 24-h profiles of cortisol levels (ie, the AUC 24 and the urinary free cortisol) and dynamic stimulation (cosyntropin) test also used herein are highly regarded assessments of the HPA axis. 4, 14 While the former is used to detect endogenous adrenocortical activity and indicates systemic exposure of the inhaled drug, the latter tests adrenal reserve and reflects on the potential for suppression of physiologic adrenal response (eg, to stress). 14 The mild quantitative differences between MF administration by DPI and MDI reported herein are consistent with the recognition by other investigators that the drug delivery system can greatly influence both the treatment efficacy and the systemic activity of inhaled corticosteroids. 1, 15 Thus, direct comparisons between different studies using different glucocorticoids with different delivery devices are not appropriate in some cases. Nevertheless, for general reference purposes, it is relevant to note that other inhaled glucocorticoids used to treat asthma (beclomethasone dipropionate, budesonide, fluticasone propionate) have been found to affect the HPA axis consistently and significantly at total doses from 800 to 1,600 g/d. 1, 4 HPA-axis suppression is an indicator of the systemic activity of inhaled glucocorticoids. The clinical significance of HPA-axis suppression by inhaled glucocorticoids is unclear. 1, 4 However, the effect of inhaled glucocorticoids on HPA-axis function can be used to relate their systemic potency to that of oral prednisone. 16 An estimate of the oral prednisone dose causing HPA-axis suppression equivalent to that caused by MF and FP in the present study was calculated. The degree of HPA-axis suppression after 28 days of treatment in the present study 3 was compared with log-dose data for the suppression of urinary cortisol after treatment for 4 weeks with oral prednisone from Vargas et al. 17 There are important concerns with this type of cross-study analysis. 1 However, using the Vargas et al 17 data, the prednisone equivalence for 64% suppression found in study 2 is calculated as 10.5 mg. This value is in excellent agreement with the 64% suppression caused by 10 mg of prednisone in the present study. Similar calculations were used to estimate an oral prednisone equivalent of 1.9 mg for the 21% HPAaxis suppression by MF, 800 g bid. Likewise, the 55% systemic effect of FP, 880 g bid, would be calculated as 7.6 mg of oral prednisone equivalents. The predicted therapeutic response of MF should be maximal for these patients with mild-to-moderate persistent asthma at about 200 g bid, 9 while that of prednisone should be only approaching maximal at about 30 mg/d. 16 The clinical implications of these prednisone equivalent doses can be placed in context by a study that examined the adverse effects associated with the use of long-term systemic oral glucocorticoids in rheumatoid arthritis. 18 Using data from long-term therapy with low-dose oral corticosteroids, average daily use of Ͻ 5 mg of prednisone (or equivalent dose of an alternate oral corticosteroid) for Ͼ 1 year did not show a significant increased risk for adverse reactions, compared to no prednisone treatment. However, average daily use of 5 to 10 mg of prednisone was associated with a significant increased risk (odds ratio of 4.5) of adverse events such as fracture, GI bleed or ulcer, or infection. 18 This suggests that in those instances in which very high doses of inhaled glucocorticoids may be appropriate, that MF, 800 g bid, may have a superior safety profile.
In conclusion, plasma levels of MF when delivered by DPI were generally negligible to low and highly variable. Single dosages of MF up to 1,200 g/d have negligible systemic effects, as reflected by a lack of consistent significant suppression of HPA-axis function when administered to patients with mild-tomoderate asthma. Although there were relatively low levels of suppression (19 to 25%) at earlier time points for MF DPI, 400 g bid, a dosage of 800 g bid (total 1,600 g/d) appears to be the lower limit where MF has minimal, yet consistently detectable systemic effects. These effects, including a modest depression of HPA-axis function, were remarkably less than caused by prednisone, 10 mg qd po, or FP, 880 g bid. The implications of these results are limited to the population studied (mild-to-moderate persistent asthma). The results in patients with acute or severe asthma have not been determined.
